Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: A prospective validation study

Haematologica

Volumn 94, Issue 8, 2009, Pages 1066-1074

  Ogata, Kiyoyuki ^a   Della Porta, Matteo G ^b   Malcovati, Luca ^b   Picone, Cristina ^b   Yokose, Norio ^a   Matsuda, Akira ^c   Yamashita, Taishi ^a,d   Tamura, Hideto ^a   Tsukada, Junichi ^e   Dan, Kazuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b UNIVERSITY OF PAVIA   (Italy)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

^e UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Diagnosis; Flow cytometry; Myelodysplastic syndromes

Indexed keywords

CD11B ANTIGEN; CD15 ANTIGEN; CD45 ANTIGEN; CD56 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL COUNT; CHROMOSOME ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DIAGNOSTIC VALUE; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PARAMETER; PRE B LYMPHOCYTE; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SIDEROBLASTIC ANEMIA; VALIDATION STUDY;

ADULT; AGED; ANTIGENS, CD11B; ANTIGENS, CD15; ANTIGENS, CD45; ANTIGENS, CD56; BONE MARROW CELLS; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 68049127978     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.008532     Document Type: Article

References (35)

1. Mufti GJ. Pathobiology, classification, and diagnosis of myelodysplastic syndrome. Best Pract Res Clin Haematol 2004;17:543-57.
2. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med 2005;352:536-8.
3. Hamblin TJ. Epidemiology of the myelodysplastic syndromes. In: Bennett JM, ed. The Myelodysplastic Syndromes. New York: Marcel Dekker; 2002. p. 15-27.
4. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999;340:1649-60.
5. Kouides PA, Bennett JM. Understanding the myelodysplastic syndromes. Oncologist 1997;2:389-401.
6. Stetler-Stevenson M, Arthur DC, Jabbour N, Xie XY, Molldrem J, Barrett AJ, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001;98:979-87.
7. Malcovati L, Della Porta MG, Lunghi M, Pascutto C, Vanelli L, Travaglino E, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005;19:776-83.
8. Cherian S, Moore J, Bantly A, Vergilio JA, Klein P, Luger S, et al. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2005;64:9-17.
9. Della Porta MG, Malcovati L, Invernizzi R, Travaglino E, Pascutto C, Maffioli M, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006;20:549-55.
10. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006;108:1037-44.
11. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727-36.
12. Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 2008;32:5-17.
13. Satoh C, Dan K, Yamashita T, Jo R, Tamura H, Ogata K. Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 2008;32:699-707.
14. ELN Diagnostic Guidelines. Proposal for standardized diagnostic and prognostic procedures in the myelodysplastic syndromes, mixed myelodysplastic/myeloproliferative disorders, and acute myeloid leukemia. LeukemiaNet WP8 MDS. 2007-09-26. http://www.leukemianet.org/content/leukemias/ mds/standards-sop/. Accessed December 24, 2008.
15. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
16. Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23:7594-603.
17. Mitelman F. ISCN 1995. An International System for Human Cytogenetic Nomenclature. Basel: Karger. 1995.
18. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89: 2079-88.
19. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-10.
20. Baumgarth N, Roederer M. A practical approach to multicolor flow cytometry for immunophenotyping. J Immunol Methods 2000;243:77-97.
21. Roederer M. Spectral compensation for flow cytometry: visualization artifacts, limitations, and caveats. Cytometry 2001;45:194-205.
22. Loken MR, Wells DA. Normal antigen expression in hematopoiesis. Basis for interpreting leukemia phenotypes. In: Stewart CC, Nicholson JKA, eds. Immunophenotyping. New York, NY: Wiley-Liss; 2000:133-60.
23. Ogata K. Diagnostic flow cytometry for low-grade myelodysplastic syndromes. Hematol Oncol 2008;26:193-8.
24. Grimes DA, Schulz KF. Refining clinical diagnosis with likelihood ratios. Lancet 2005;365:1500-5.
25. Leemis LM, Trivedi KS. A comparison of approximate interval estimators for the Bernoulli parameter. The American Statistician 1996;50:63-8.
26. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood 2005;106:2633-40.
27. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003;102:394-403.
28. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 2006;125:884-94.
29. Kussick SJ, Fromm JR, Rossini A, Li Y, Chang A, Norwood TH, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005;124:170-81.
30. McCormack RT, Nelson RD, LeBien TW. Structure/function studies of the common acute lymphoblastic leukemia antigen (CALLA/CD10) expressed on human neutrophils. J Immunol 1986;137:1075-82.
31. Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002;100:3887-96.
32. Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 2008;111:3998-4003.
33. Reid MC, Lane DA, Feinstein AR. Academic calculations versus clinical judgments: practicing physicians' use of quantitative measures of test accuracy. Am J Med 1998;104:374-80.
34. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008;111:1067-77.
35. Matarraz S, Lopez A, Barrena S, Fernandez C, Jensen E, Flores J, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia 2008;22:1175-83.